L.E.L. Hendriks

Vaes, R. D. W., Cortiula, F., Lyu, S., Hiltermann, T. J. N., Houben, R., Degens, J., Hendriks, L. E. L., & Ruysscher, D. D. (2025). Chemoradiotherapy efficacy in patients with stage III non-small cell lung cancer (NSCLC): A prognostic clinical and biomarker-based model. Lung Cancer, 203, Article 108541. https://doi.org/10.1016/j.lungcan.2025.108541

Houdaa, I., Bahcea, I., Remonb, J., Berghmansc, T., Faivre-Finnd, C., Dingemansf, A.-M. C., Besseb, B., & Hendriksg, L. E. L. (2025). Response to "Letter to Editor-in-Chief" and "Redefining Resectability: Bridging Perspectives in Stage III NSCLC Management". Lung Cancer, 203, Article 108510. https://doi.org/10.1016/j.lungcan.2025.108510

Guckenberger, M., Opitz, I., Dellaporta, T., Curioni-Fontecedro, A., Frauenfelder, T., Ribi, K., Cerciello, F., Sullivan, I., Hendriks, L., Dorta, M., Callejo, A., Aerts, J., Addeo, A., Dingemans, A. M. C., Pasello, G., Provencio, M., de Marinis, F., Mederos-Alfonso, N., Roschitzki-Voser, H., ... Stahel, R. (2025). Multimodality treatment in synchronous oligometastatic NSCLC: Analysis of the ETOP CHESS trial. Lung Cancer, 204, Article 108553. Advance online publication. https://doi.org/10.1016/j.lungcan.2025.108553

Heersche, N., Lanser, D. A. C., Muntinghe-Wagenaar, M. B., Mohmaed Ali, M. I., Ulas, E. B., Trooster, T. M. A., de Jonge, E., Oomen-de Hoop, E., Paats, M. S., Bahce, I., Croes, S., Hendriks, L. E. L., van der Wekken, A. J., Dingemans, A.-M. C., Huitema, A. D. R., van Schaik, R. H. N., Mathijssen, R. H. J., & Veerman, G. D. M. (2025). Sex and Common Germline Variants Affect the Toxicity Profile and Pharmacokinetics of Alectinib: A Nationwide Cohort Study in Patients With ALK-Positive NSCLC. Journal of Thoracic Oncology, 20(4), 475-486. https://doi.org/10.1016/j.jtho.2024.11.025

Brouns, A. J. W. M., Robbesom-Van den Berge, I. J., Ernst, S. M., Steendam, C. M. J., Woud, W. W., Wu, L., Dingemans, A. M. C., Hendriks, L. E. L., & van Driel, M. (2025). Connecting the dots: (RANKL⁺) extracellular vesicle count in blood plasma in relation to bone metastases, skeletal related events and osimertinib treatment in patients with EGFR mutated non-small cell lung cancer. Translational Lung Cancer Research, 14(3), 761-774. https://doi.org/10.21037/tlcr-24-1007

Remon, J., Bortolot, M., Bironzo, P., Cortiula, F., Menis, J., Brandao, M., Naidoo, J., van Geel, R., Reguart, N., Arrieta, O., Mountzios, G., Hendriks, L. E. L., & Besse, B. (2025). De-Escalation Strategies With Immune Checkpoint Blockers in Non-Small Cell Lung Cancer: Do We Already Have Enough Evidence? Journal of Clinical Oncology, 43(9), 1148-1156. Article 2402347. https://doi.org/10.1200/JCO-24-02347

Noordhof, A. L., Blum, T. G., Hardavella, G., Hendriks, L. E. L., & van Geffen, W. H. (2025). Editorial: KRAS in stage IV non-small cell lung cancer. Frontiers in Oncology, 14, Article 1517049. https://doi.org/10.3389/fonc.2024.1517049

Mountzios, G., Saw, S. P. L., Hendriks, L., Menis, J., Cascone, T., Arrieta, O., Naidoo, J., Koutoukoglou, P., Cani, M., Lefevre, A., Addeo, A., Peters, S., & Remon, J. (2025). Antibody-drug conjugates in NSCLC with actionable genomic alterations: Optimizing smart delivery of chemotherapy to the target. Cancer Treatment Reviews, 134, Article 102902. https://doi.org/10.1016/j.ctrv.2025.102902

Jongbloed, M., Bartolomeo, V., Bortolot, M., Darwesh, S., Huijs, J. W. J., Dursun, S., Degens, J., van den Borne, B. E. E. M., Youssef-El Soud, M., Westenend, M., Pitz, C., De Ruysscher, D. K. M., & Hendriks, L. E. L. (2025). Impact of Immune Checkpoint Inhibitors and Local Radical Treatment on Survival Outcomes in Synchronous Oligometastatic NSCLC. JTO Clinical and Research Reports, 6(3), Article 100790. https://doi.org/10.1016/j.jtocrr.2025.100790

Le, X., Eisert, A., Hsia, T.-C., Raut, N. V., Ahmad, A., Chan, O. S. H., De Bondt, C., Farrugia, D., Froesch, P., González-Cao, M., Hendriks, L., Hochmair, M. J., Mazieres, J., O'Sullivan, H., Popat, S., Samol, J., van der Wekken, A. J., Yang, T.-Y., Tho, L. M., ... Chang, G.-C. (2025). Tepotinib Plus an EGFR Tyrosine Kinase Inhibitor in Patients With EGFR-Mutant MET-Altered NSCLC: A Case Series. Clinical Lung Cancer. Advance online publication. https://doi.org/10.1016/j.cllc.2025.02.013